Good morning :)
$
₹
ProPhase Labs Inc

ProPhase Labs Inc

PRPH

NASDAQ
Asset Logo

ProPhase Labs Inc

PRPH

NASDAQ
$0.3618.97% (-0.08)
$
₹
$0.3618.97% (-0.08)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Unknown

Sector and industry information not available

Micro Cap

With a market cap of $1.9M the stock is ranked 6151

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.27
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-19.8
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Price Upside

+5532.65%

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Prenetics Global Ltd
PRE
Prenetics Global Ltd
P/E Ratio
—
—
1Y Return
0.17%
0.17%
Buy Reco %
100.00
100.00
Precipio Inc
PRPO
Precipio Inc
P/E Ratio
—
—
1Y Return
8.71%
8.71%
Buy Reco %
100.00
100.00
MDxHealth SA
MDXH
M
P/E Ratio
—
—
1Y Return
95.83%
95.83%
Buy Reco %
16.66
16.66
ENDRA Life Sciences Inc
NDRA
ENDRA Life Sciences Inc
P/E Ratio
0.19
0.19
1Y Return
20.33%
20.33%
Buy Reco %
100.00
100.00
iSpecimen Inc
ISPC
iSpecimen Inc
P/E Ratio
—
—
1Y Return
97.33%
97.33%
Buy Reco %
100.00
100.00
Compare with Peers

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
ProPhase Labs Inc -0.270
Prenetics Global Ltd-1.300
Precipio Inc-3.230
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PRPH with any stock or ETF
Compare PRPH with any stock or ETF
Comparing from
PRPH
PRE
PRPO
Loading...

Frequently asked questions

  1. ProPhase Labs Inc (PRPH) share price today is $0.36 as of January 3, 2026 at 1:30 AM IST. The stock touched a day high of $0.00 and a day low of $0.00.

  2. ProPhase Labs Inc stock trades on NASDAQ under the ticker symbol PRPH.

  3. ProPhase Labs Inc's market capitalization is $1.89M as of January 3, 2026 at 1:30 AM IST.

  4. ProPhase Labs Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. ProPhase Labs Inc's price-to-book (P/B) ratio is 0.27 as of October 26, 2026.

  6. Yes, You can buy ProPhase Labs Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy ProPhase Labs Inc shares in three steps: 1. Search ProPhase Labs Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since ProPhase Labs Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in ProPhase Labs Inc (PRPH) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 27.5785 shares at the current price of $0.36.

Loading...